Circulating concentrations of interleukin-2 (IL-2) and a soluble or shed form of the IL-2 receptor (sIL-2R) were determined by enzymelinked immunosorbent assays (ELISA) in 61 patients with chronic active Crohn's disease (CD) initially and during a three month placebo controlled trial of cyclosporin 5-7-5 mg/kg! day. The baseline median (25-75% range) plasma IL-2 concentration was 0-6 ng/ml (0 3-2 85 ng/ml) in patients who did not receive prednisolone, 05 ng/ml (0.23-3.4 ng/ml) in patients who did (not significant), and 0 ng/ml (0-0-07 ng/ml) in control subjects (p<0.00001). The corresponding median serum sIL-2R concentrations were 747 U/ml (580-1287 U/ml), 540 U/ml (422-616 U/mI) respectively in CD patients (p=0006) and 320 U/ml (268-406 U/ ml) in control subjects (p<000001). Increased concentrations of plasma IL-2 and serum sIL-2R were seen in 66% and 81% of the patients, respectively. A fail in serum sIL-2R was only seen in patients who improved with cyclosporin treatment (p-0.006). At month 3 the median serum sIL-2R concentration was 440 U/ml (400-668 U/ml) v 801 U/ml (534-1067 U/ml) in patients not responding to cyclosporin (p=0 003). No changes occurred in the placebo group. These results suggest that the IL-2 dependent pathway of immune activation is upregulated in vivo in CD and that cyclosporin may interfere with this process.
Interleukin-2 (IL-2) functions as an obligatory signal for T cell growth, and this ligand effect is mediated through a specific T cell surface receptor (IL-2R). IL-2 production and IL-2R expression are determined by antigen recognition or mitogen stimulation.' In vitro studies on isolated mononuclear cells, using bioassays, suggest that the production of IL-2 may be impaired in active Crohn's disease (CD),2A even though T cells appear to be activated in this disease.5 Accordingly, we have recently shown that cyclosporin, a potent inhibitor of IL-2 production by T cells,6 has a beneficial therapeutic effect on chronic active CD. 7 Specific enzyme-linked immunosorbent assays (ELISAs) are now available for the determination of IL-2 and a soluble/shed form of IL-2R (sIL-2R) in vivo, using plasma or serum. 8 Clinical studies have shown that conditions characterised by enhanced T cell mediated immunity in vivo, such as transplant rejection, are, associated with high concentrations of IL-2 or sIL-2R, or both."" Therefore, it seemed of interest to determine circulating IL-2 and sIL-2R concentrations as measures of continuing T cell activation in CD. Furthermore, in longitudinal studies we investigated whether these measurements might be a means of monitoring cyclosporin treatment.
Methods
Serial serum and heparin-stabilised plasma samples were collected at five of six centres participating in a three-month placebo controlled trial of cyclosporin 5-7-5 mg/kg/day in patients with chronic active CD.7 Serum samples were available for 59 [tmol/l); reference interval [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] iimol/l. There were no significant differences in baseline characteristics between patients treated with cyclosporin and those receiving placebo. The patients were studied before treatment, after two weeks of treatment, and then monthly and were classified as either improved or not improved according to a modified clinical grading score. 7 13 Nineteen healthy subjects (median age 38 years, range 28-61 years) served as controls for the IL-2 assay and another 21 
Results
The baseline median (25-75% range) plasma IL-2 concentration was 0-6 ng/ml (0-3-2 85 ng/ml) in patients not receiving prednisolone, 0 5 ng/ml (0-23-3-4 ng/ml) in patients who did receive prednisolone (not significant), and 0 ng/ml (0-0-07 ng/ml) in control subjects (p<O-00001) (Fig 1) . There was no correlation between plasma IL-2 levels and plasma orosomucoid levels or Crohn's Disease Activity Index values. Plasma IL-2 concentrations above the total range observed in healthy controls (0-3 ng/ml) were seen in 66% of the patients, and very high concentrations in two patients.
The corresponding median serum sIL-2R concentrations were 747 U/ml (580-1287 U/ml) and 540 U/ml (422-616 U/ml) in CD patients (p=0006) without and with steroid medication respectively, and 320 U/ml (268-406 U/ml) in control subjects (p<0 00001) (Fig 2) . There was a significant correlation between serum sIL-2R and plasma orosomucoid concentrations (r(S)= 0 55, p=0 00008), but not between sIL-2R concentrations and Crohn's Disease Activity Index values. By contrast, significant correlations were found among changes in sIL-2R concentrations and grading score totals, which measured changes in disease activity, at month 3 (r(S)=0 429, p=0 01) as well as at earlier points of evaluation. Increased serum sIL-2R concentrations (>470 U/ml) were seen in 81% of the patients. There was no correlation between plasma IL-2 and serum IL-2R concentrations.
EFFECTS OF TREATMENT
No significant changes were observed in plasma IL-2 either within or between treatment groups (Table II) .
Discussion
This study showed high circulating concentrations of IL-2 and sIL-2R in patients with chronic active CD compared with healthy control subjects. Although the majority of the CD patients showed only slightly raised plasma IL-2 concentrations, the fact that about two thirds of these values were above the range found in healthy subjects (Fig 1) This study suggests that serum sIL-2R may be a marker of disease activity in CD, in contrast to plasma IL-2. The finding, however, of a significantly decreased median serum sIL-2R concentration only in patients who improved with cyclosporin treatment at month 3 as well as a strong significant trend throughout the treatment period (Table II) may be of even greater interest. A simple explanation would be that serum sIL-2R is a marker of an acute-phase response, but a tendency towards an increase was seen in patients who improved with placebo (Table II) . Another possibility is that suppression of IL-2 production itself leads to decreased sIL-2R release since the ligand regulates the expression of IL-2R. 29 The finding, however, of unchanged serum sIL-2R in patients who failed with cyclosporin makes this less likely. The effect of cyclosporin on IL-2R expression is obscure. Conflicting results have been obtained in vitro, and the expression seems to depend on the type of stimulation,6 suggesting that cyclosporin exerts no direct effect on IL-2R expression.
Finally, the decline in serum sIL-2R concentrations in patients who improved with cyclosporin treatment may reflect a drug induced diminished T cell activation. Hence Baker and Jewell3' have recently reported that cyclosporin clears the expression of HLA-DR antigens on colonic epithelial cells, normally for responsible activation of T-helper cells. These findings are in keeping with the prevailing concept that activated immunological effector mechanisms occur in CD as a result of an increased antigen stimulation.5 But, owing to the considerable variation in sIL-2R suppression, this measure cannot be used to monitor cyclosporin treatment in individual patients.
Taken together the results suggest that the IL-2 dependent pathway of immune activation is upregulated in vivo in CD and that cyclosporin treatment may interfere with this process. Further studies are, however, needed to detail the effects of cyclosporin in CD.
Correction Abnormal gastric adaptive relaxation in patients with gastrooesophageal reflux by M N Hartley, S J Walker, C R Mackie. May 1990 issue, pp 500-3. In this article several lines of text in the Methods section were transposed.
The corrected text appears below.
Methods

SUBJECTS
Fifteen normal healthy volunteers were studied. These were 13 men and two women, with a median age of 30 years (range 22-41) and a median body weight of 70 kg (range 50-79) kg. Twelve patients with symptomatic gastrooesophageal reflux were studied. They were eight men and four women, with a median age of 48 years (range 23-65) and a median body weight of 77 kg (range 60-92 kg). All subjects in the control group were asymptomatic. Among patients in the reflux group, eight were complaining of regurgitation, 11 of heartburn, and four of dysphagia.
The presence of pathological gastrooesophageal reflux was confirmed in all patients in the reflux group by 24 hour ambulatory oesophageal pH monitoring. Pathological gastrooesophageal reflux was defined as the presence of one or more of the following criteria: total reflux time greater than 6%, erect reflux time greater than 8%, supine reflux time greater than 2%; more than two reflux episodes longer than five minutes. A reflux episode was defined as a drop in pH to 4 or less.
Endoscopy showed macroscopic oesophagitis in seven patients, associated with a hiatus hernia in four patients. Five patients had no abnormality at endoscopy. None of the subjects in the control group was on any medication and all medication was withheld for 12 hours before the study in all patients. After an overnight fast, subjects swallowed, via the nose a lOF Ryle's tube with a collapsed, plastic bag (800 ml) sealed over the end, the side holes of the tube being within the bag. Within (Fig 1) . A dynamic and static pressure index was derived for each subject, sitting and supine, based on the mean of the two values for each. These data were used to assess the effect of posture on gastric adaptive relaxation and also to compare the dynamic and static methods. Statistical analysis was by the Wilcoxon's signed-rank sum test for the former and the Mann Witney U test for the latter. The reproducibility of the technique was assessed in duplicate studies on separate days among eight healthy volunteers, seven of whom were drawn from the control group for this study. The eighth subject gave a history of reflux symptoms and was therefore excluded from the control group for the main study. Reproducibility was expressed as the Spearman rank correlation coefficient calculated from the pressure indices obtained from paired studies. Finally, in view of the differences in ages and body weights between the two groups, a multiple regression model was created to see if there was any effect of these two variables on pressure index (Statistical Analysis System package, SAS Institute Inc, NC 27511, USA). 
